Hologic Inc. plans to acquire Cynosure Inc.for about $1.65bn to add medical aesthetics products to its existing range of OB/GYN and women’s health technologies.
Hologic will pay $66 per share in cash for Cynosure, a 28% premium over Cynosure’s closing price before the deal was announced. Net of cash, the enterprise valve of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?